NASDAQ:ZURA Zura Bio (ZURA) Stock Price, News & Analysis $4.38 -0.02 (-0.45%) (As of 11/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Zura Bio Stock (NASDAQ:ZURA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Zura Bio alerts:Sign Up Key Stats Today's Range$4.26▼$4.4250-Day Range$3.30▼$4.9252-Week Range$2.00▼$6.35Volume122,531 shsAverage Volume324,716 shsMarket Capitalization$294.37 millionP/E RatioN/ADividend YieldN/APrice Target$17.33Consensus RatingModerate Buy Company OverviewZura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.Read More… Sell NVDA Now? (Ad)Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.Now he's just issued a warning for the most popular stock in the world: Nvidia (NVDA). Zura Bio Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks52nd Percentile Overall ScoreZURA MarketRank™: Zura Bio scored higher than 52% of companies evaluated by MarketBeat, and ranked 571st out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingZura Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageZura Bio has only been the subject of 3 research reports in the past 90 days.Read more about Zura Bio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Zura Bio are expected to decrease in the coming year, from ($0.47) to ($0.80) per share.Price to Book Value per Share RatioZura Bio has a P/B Ratio of 2.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Zura Bio's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.45% of the float of Zura Bio has been sold short.Short Interest Ratio / Days to CoverZura Bio has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Zura Bio has recently increased by 1.08%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldZura Bio does not currently pay a dividend.Dividend GrowthZura Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.45% of the float of Zura Bio has been sold short.Short Interest Ratio / Days to CoverZura Bio has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Zura Bio has recently increased by 1.08%, indicating that investor sentiment is decreasing. News and Social Media1.8 / 5News Sentiment0.15 News SentimentZura Bio has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Zura Bio this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for ZURA on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Zura Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $200,187.00 in company stock.Percentage Held by Insiders22.10% of the stock of Zura Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.14% of the stock of Zura Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Zura Bio's insider trading history. Receive ZURA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zura Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address ZURA Stock News HeadlinesZura Bio to Participate in Two Upcoming Investor Conferences in NovemberOctober 30 at 10:38 AM | businesswire.comReviewing CG Oncology (NASDAQ:CGON) & Zura Bio (NASDAQ:ZURA)October 29, 2024 | americanbankingnews.comSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.November 2, 2024 | Chaikin Analytics (Ad)Zura Bio (NASDAQ:ZURA) Stock, Short Interest ReportOctober 29, 2024 | benzinga.comZura Bio (NASDAQ:ZURA) Stock Quotes, Forecast and News SummaryOctober 29, 2024 | benzinga.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Universal Health (UHS), Apellis Pharmaceuticals (APLS) and Zura Bio (ZURA)October 29, 2024 | markets.businessinsider.comZura Bio (NASDAQ:ZURA) Rating Reiterated by HC WainwrightOctober 23, 2024 | americanbankingnews.comZura Bio’s Leadership Instability and Uncertain Prospects Lead to Hold RatingOctober 23, 2024 | markets.businessinsider.comSee More Headlines ZURA Stock Analysis - Frequently Asked Questions How have ZURA shares performed this year? Zura Bio's stock was trading at $4.67 at the start of the year. Since then, ZURA shares have decreased by 6.2% and is now trading at $4.38. View the best growth stocks for 2024 here. How were Zura Bio's earnings last quarter? Zura Bio Limited (NASDAQ:ZURA) posted its quarterly earnings results on Tuesday, August, 13th. The company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by $0.02. Who are Zura Bio's major shareholders? Zura Bio's top institutional investors include Palumbo Wealth Management LLC (0.06%) and SG Americas Securities LLC (0.03%). Insiders that own company stock include Someit Sidhu, Van Amstel Arnout Ploos, Michael Howell and Kiran Nistala. View institutional ownership trends. How do I buy shares of Zura Bio? Shares of ZURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Zura Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zura Bio investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Walt Disney (DIS). Company Calendar Last Earnings8/13/2024Today11/02/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ZURA CUSIPN/A CIK1855644 WebN/A Phone858-247-0520FaxN/AEmployees3Year FoundedN/APrice Target and Rating Average Stock Price Target$17.33 High Stock Price Target$26.00 Low Stock Price Target$5.00 Potential Upside/Downside+295.7%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-69,240,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-28.83% Return on Assets-22.91% Debt Debt-to-Equity RatioN/A Current Ratio12.57 Quick Ratio12.57 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.85 per share Price / Book2.37Miscellaneous Outstanding Shares67,207,000Free Float52,354,000Market Cap$294.37 million OptionableOptionable Beta0.16 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report This page (NASDAQ:ZURA) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | SponsoredWall St. Legend: Millions of Americans About to Fall Out of the 1%Wall Street insider reveals the financial tidal wave about to knock millions of Americans out of the One Perce...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zura Bio Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Zura Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.